Overview
BAO PHARMA-B (2659)
Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainl...
- Open
- 10.010
- High
- 12.080
- Low
- 9.990
- Prev. Close
- 10.440
- Volume
- 6.74M
- Turnover
- 75.40M
- Avg Price
- 11.185
- Bid/Ask Ratio
- 55.79%
- Amplitude
- 20.02%
- 52wk High
- 206.000
- Volume Ratio
- 11.46
- Turnover Ratio
- 4.45%
- 52wk Low
- 6.475
- HK Mkt Cap
- 1.83B
- Market CapHKD
- 3.90B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.30
- EPSDynamic
- -1.09
- EPSStatic
- --
- BVPS
- 5.16
- P/B
- 2.34
- HK Shares
- 151.54M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 323.19M
- Min lot size
- 100
- Currency
- HKD
Daily Events
- Nov, 16
Bao Pharma-B opened lower at HK$10.01 but reversed to close at HK$12.08, up 15.71%, swinging from an intraday low of HK$9.99 to a session high of HK$12.05 on HK$73.8 million of turnover. The driver remains the continued digestion of BJ045's IND approval and the chairman's stake purchase, lifting the shares about 15% for the week and onto Hong Kong's top-10 gainers list. The fundamentals cut the other way: Q2 2026 revenue was only HK$5.70 million, down 75.21% year on year, while the net loss of HK$88.76 million narrowed 11.52%. At HK$12.08 the stock has just reclaimed its MA20 of HK$8.884 yet still sits below the MA60 of HK$12.109, 94.14% below the 24 February high of HK$206 and down 82.67% year to date, though 86.56% above the 22 October low of HK$6.475. Revenue halving while losses persist leaves the durability of the rebound dependent on pipeline progress.
- Nov, 13
Bao Pharma-B reversed early gains to close at HK$10.42, down 8.6%, giving back part of last week's advance driven by BJ045 IND clearance and the chairman's open-market share purchase; the stock touched HK$11.69 at 09:33 before sliding to HK$10.30 by 15:17. Turnover reached 4.87 million shares worth HK$53.71 million, a 3.21% turnover rate. The close sits above the MA20 of HK$8.768 but below the MA60 of HK$12.178, down 85.05% year-to-date, 94.94% below the HK$206 high of 24 February, yet 60.93% above the HK$6.475 low of 22 October. Q2 2026 revenue was HK$5.70 million, down 75.21% year-on-year, while the net loss of HK$88.76 million narrowed 11.52% and loss per share was HK$0.2723; with negative earnings the PE stands at -7.99 and PB at 2.02. Though single-week declines of 18.85% earlier in this cycle show how volatile the register remains.
- Nov, 12
Bao Pharma-B opened lower, rallied through the afternoon and then pared gains, closing at HK$11.37 for a 20.8% advance as BJ045's clinical trial clearance and the chairman's stake purchase kept circulating in weekly recaps; the stock spiked to HK$13.21 at 15:17 BJ from a morning low of HK$9.28, with turnover swelling to HK$193 million and a turnover rate of 11.13%. Fundamentals remain under pressure: Q2 2026 revenue was just HK$5.70 million, down 75.21% year on year, while the net loss of HK$88.76 million narrowed 11.52%, EPS came in at -HK$0.2723 and ROE at -21.22%. The price now sits above the MA20 of HK$8.735 but below the MA60 of HK$12.274, down 83.69% year to date and 94.48% below the February 24 52-week high of HK$206, though still 75.6% above the October 22 low of HK$6.475. Though the rebound rests on a single pipeline event and insider buying, with no visible recovery on the revenue line.
- Nov, 11
Bao Pharma-B staged a spike-and-fade session: it opened at HK$9.58, touched HK$10.08 in the morning, then gave back gains to close at HK$9.415, up 2.56% from the prior HK$9.18 close on 3.31 million shares and HK$31.7 million turnover, as residual momentum from BJ045 IND clearance and the chairman's stake purchase carried into a week that had earlier added nearly 10%. Fundamentals cut the other way: Q2 2026 revenue was only HK$5.70 million, down 75.21% year on year, with a net loss of HK$88.76 million and a -1556.3% net margin, though the loss narrowed 11.5% and EPS was -HK$0.2723. At HK$9.415 the stock sits 95.43% below its 52-week high of HK$206 and is down 86.49% year to date; it holds above the 20-day MA of HK$8.67 but below the 60-day MA of HK$12.36, with PB at 1.82x. Still, the price remains 45.41% above the 22 October low of HK$6.475, and small-cap biotech swings stay wide.
- Nov, 6
Bao Pharma-B opened lower, spiked to HK$9.685 in the morning, then faded through the afternoon to HK$8.725 and closed at HK$8.78, down 5.18% from the previous close of HK$9.26; turnover was HK$44.4 million. The move came after an earlier 12% jump linked to China NMPA approval of the BJ045 injection IND and Chairman Liu Yanjun’s purchases of 263,300 shares over three days for about HK$2.0243 million, plus 102,100 shares at roughly HK$7.44 each. Q2 2026 revenue was HK$5.703 million, down 75.21% year on year, and the net loss was HK$88.756 million, while EPS improved 21.82% year on year but stayed negative. At HK$8.78 the stock is below its 20-day MA of HK$8.946 and 60-day MA of HK$12.743, down 87.4% year to date and 95.74% below the 52-week high of HK$206, though it remains 35.6% above the 52-week low of HK$6.475. Its market capitalization is about HK$2.84 billion, with a negative PE of -6.74 and PB of 1.70. The intraday high at 09:44 BJ time failed to hold, and the afternoon low at 13:59 BJ time marked the weakest point.
News
Weekly Review · Weekly Recap | BAO PHARMA-B +15.36%, surging against a falling market
Market Movers · Bao Pharma surges 12%
Market Movers · Bao Pharma climbs 6%
Weekly Review · Weekly Recap | BAO PHARMA-B +9.61%, BJ045 approval and chairman buying drive rally
Market Movers · Bao Pharma surges 12% on BJ045 IND approval and chairman stake buy
Market Movers · BAO PHARMA-B fell approximately 6%
